Patent ID: 7858390

Claim:
A method of determining whether a colorectal cancer (CRC) patient is likely to benefit from treatment with a monoclonal antibody epidermal growth factor receptor inhibitor drug targeting the EGFR pathway, comprising the steps of: a) obtaining a mass spectrum from a blood-based sample from the CRC patient; b) performing one or more predefined pre-processing steps on the mass spectrum obtained in step a); c) obtaining integrated intensity values of selected features in said spectrum at one or more predefined m/z ranges after the pre-processing steps on the mass spectrum in step b) have been performed; and d) using the values obtained in step c) in a classification algorithm using a training set comprising class-labeled spectra produced from blood-based samples from other cancer patients to identify the CRC patient as being either likely or not likely to benefit from treatment with the said monoclonal antibody epidermal growth factor receptor inhibitor drug.